Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction - Wikidata - awgldk - TriplyDB

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

http://www.wikidata.org/entity/Q34625223

about

Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis Improved Cardiovascular Disease Outcomes in Older Adults Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review Patient selection in heart failure with preserved ejection fraction clinical trials Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction Mechanistic Pathways of Sex Differences in Cardiovascular Disease.Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia.Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort.Pulmonary vascular volume, impaired left ventricular filling and dyspnea: The MESA Lung Study.Prognostic significance of depression in blacks with heart failure: insights from Heart Failure: a Controlled Trial Investigating Outcomes of Exercise Training.Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue.Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction.Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction.Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides.Multimorbidity in Heart Failure: Effect on Outcomes.Follistatin like 1 Regulates Hypertrophy in Heart Failure with Preserved Ejection Fraction A Gordian knot: disentangling comorbidities in heart failure Circulating Fibroblast Growth Factor 21 is Associated with Diastolic Dysfunction in Heart Failure Patients with Preserved Ejection Fraction.Patterns of scheduled follow-up appointments following hospitalization for heart failure: insights from an urban medical center in the United States.The vulnerable patient with chronic kidney disease.Risk Factors for Incident Hospitalized Heart Failure With Preserved Versus Reduced Ejection Fraction in a Multiracial Cohort of Postmenopausal Women Diastolic function in heart failure.Cardiometabolic Disease Leading to Heart Failure: Better Fat and Fit Than Lean and Lazy.Pathophysiology and clinical evaluation of acute heart failure.Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.Comorbidities in Heart Failure: Are There Gender Differences?Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond.Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults.Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.Sex- and Race-Related Differences in Characteristics and Outcomes of Hospitalizations for Heart Failure With Preserved Ejection Fraction Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care.Obstructive Ventilatory Disorder in Heart Failure-Caused by the Heart or the Lung?Phenotype-Specific Association of Single-Nucleotide Polymorphisms with Heart Failure and Preserved Ejection Fraction: a Genome-Wide Association Analysis of the Cardiovascular Health Study.Sex Differences in Metabolic Cardiomyopathy.Evaluation of the predictors of readmission in Korean patients with heart failure.Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies.Sex and Cardiovascular Involvement in Inflammatory Joint Diseases.Elevated serum osteoprotegerin is associated with increased left ventricular mass index and myocardial stiffness.Novel Urinary Peptidomic Classifier Predicts Incident Heart Failure.

P2860

Q26751460-3E1F74C7-DA72-46DB-A2A7-6CE5A2C0805E Q26766094-B1BFA1D3-C347-4384-8271-2BB22308C2E6 Q26779538-7885E1C0-0123-49AA-9B14-8993BACC9025 Q27015845-0CCF0EE4-533A-4370-990D-1362BEDA774F Q28073079-66B49D7A-1E9E-45E4-AC7A-27F359838458 Q30241924-04AC3697-4F7A-42A4-B78D-B70BE5731872 Q30250020-6ED448EA-B588-4781-9AD9-BCD89B0CBB46 Q31071475-3908EE89-C7FC-436C-B21B-D93463E897D9 Q33585317-B22F397E-AFE0-40D8-AD8D-311AA981374C Q35629922-64B637B1-DB84-4BEF-A7A8-9828FF641DB2 Q35882942-00CB224C-18FB-4EE5-9782-0E9782F17B5F Q36053833-DE28363C-16DC-4BCD-BBC6-894986F3CDF1 Q36171125-3E8E3A51-B56F-477A-B04E-E2BBC0138870 Q36698463-E6AB4FE7-2553-4725-9160-E470C81AA71E Q37092081-FE4131E8-53E5-4F42-80BA-6EFAD10F87A2 Q37094365-1D6D9908-B5E4-40BC-9388-ED19F8D788F2 Q37104287-85B687C8-4729-430B-BFF6-EF8D584BF4DE Q37271698-7D0F916C-9283-449B-AB60-0EE49E485903 Q37300799-0343A321-11CC-4558-902A-8FFF42B2DF4D Q38368207-B4FA793E-89BC-49EA-A4BD-D4D8651940A0 Q38387058-15923413-5D0D-49A2-8C06-154FB09DF6CE Q38448438-CA8644C9-96F1-4359-8715-5A7156147621 Q38571829-875B335F-CE0A-4E28-B2A0-628F08C95355 Q38586834-2B5CC134-80B7-42D8-BB8F-ED3626E7655F Q38638655-62360EA9-AA1C-4AE2-A0AA-B826E9BF6258 Q38717849-46B758E0-C6F3-442A-87EE-CA1788ACC338 Q38744467-678ABD12-C1A0-4281-92ED-EDF0B1CBB562 Q38748465-DE6548AF-7F1F-4C51-A225-0AF4C5148E29 Q38762394-CECA6F22-8A9A-4EC6-969E-C673DD282F2A Q38807777-8CDDEC25-9B49-4A3A-A205-1804FA06C4E8 Q38868414-7100AE51-5F0E-4531-A706-51787084FF99 Q38944856-527E016E-5C99-4A69-B390-5D4850183E6F Q39000103-660ABF8C-35A3-4E61-A730-1ECC6785D8D8 Q39010896-65C2F8C2-4694-475E-9524-EE91CB46DFE0 Q39118050-81C24345-2ED8-4875-B785-A7F1B985A1BA Q39239623-B3438AD1-56B0-43F6-A27D-D9BD418255D8 Q39432098-589E39FC-EC3C-4EBF-BD0C-109CE53BC666 Q40065441-A2660747-3328-4B6A-9666-96D03BE7F96F Q40090827-860AEEEE-65F3-4C97-9C9F-D1DE51442878 Q40091740-02439D53-BA9B-4081-898A-52C8D5EB5445

P2860

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

http://www.wikidata.org/entity/Q34625223

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

@ast

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

@en

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

@nl

type

label

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

@ast

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

@en

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

@nl

prefLabel

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

@ast

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

@en

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

@nl

P1433

Q34625223-035B0EC2-7573-4057-992D-6F0E35CA6D94

P1476

Q34625223-B176C53A-D682-4B97-9BFD-DC9EAC04F145

P2093

Q34625223-129494A3-EFCD-405A-B023-8DFD5565E3E4

Q34625223-1FAB8E38-7428-4029-9FF0-C9F3FC053217

Q34625223-4BCC6A2C-8C91-4E0C-8F83-E1056922A30A

Q34625223-65525889-78D8-495A-945D-6110BEA91F0B

Q34625223-9B289FD8-649B-478F-B1D7-D7214D5E87ED

Q34625223-9BCFD59B-C7B0-41F9-B310-3C7100C44CE0

Q34625223-A04AB640-5EF5-4468-8610-17A01512C204

Q34625223-C0494096-77D4-4C17-8625-54BEF9B36EE7

P2860

Q34625223-00DF13D0-3C61-4E9C-853B-60523515980B

Q34625223-01E81141-B6E2-4F2B-A83A-8FDAF80888A7

Q34625223-05422232-B4C4-4C1C-9581-997860EBE922

Q34625223-08798A5B-61B2-4F85-9CE0-2CFCCEF7B4B3

Q34625223-0AFBF52F-F27F-4A71-AD36-4403E87E29E8

Q34625223-0B32D6B3-6879-4ACE-B3A8-DF610B240050

Q34625223-0F1EB76B-F7E4-4006-A143-47E8F4F7AF29

Q34625223-0FD6B14E-7B20-4924-A45C-1EEA939392CE

Q34625223-16EDEB42-7AB2-4985-9213-B9094CCF00FB

Q34625223-178FAB25-1B9B-479A-A99D-D3BD1D72837D

P304

Q34625223-81F5BD87-2819-4899-BB3C-C29253B1084A

P31

Q34625223-F766C669-E5DC-469F-80D2-74C6893E5762

P356

Q34625223-3C4263E1-A17C-47D2-8877-8E475BCD86FC

P407

Q34625223-B03A3655-FE9A-48EA-86C7-62100F5DC8AD

P433

Q34625223-007384DE-5DC2-42CE-8337-F915AF58EA7C

P478

Q34625223-489A5F99-F46C-42BC-BC91-A676CC993866

P50

Q34625223-03E64DFD-9987-4B3E-BBF3-9754F52D3B52

Q34625223-14B152D7-E6E4-45F6-AC23-9B6B1B8F79C2

Q34625223-912F5673-FE36-4FF8-B0FE-6F82D9667B20

Q34625223-94033A39-7965-4A2C-A49D-BC0DC7845B43

Q34625223-D1C4DB38-4C17-4160-81BF-07AF52B8ECF2

Q34625223-DC979C85-9ADB-439F-9982-94700CDFB420

Q34625223-EEB38FF6-944A-4B95-A4FF-88EFFCDBD58A

P577

Q34625223-317C9782-4117-4598-A3AD-2CBBAC14123A

P5875

Q34625223-F8C01E28-BE7E-4BAE-98C6-25FD973ED418

P698

Q34625223-2F6B1516-43E2-4616-8147-1B4DBE1A44C6

P921

Q34625223-F31D516A-642E-4F78-AB85-DDFBB582FAF8

P932

Q34625223-87D12B40-4FA5-44D9-BB04-08D13ACC6679

P356

J.JACC.2014.08.036

P1433

Journal of the American College of Cardiology

P1476

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

@en

P2093

Adriaan A Voors

http://www.w3.org/2001/XMLSchema#string

Carolyn S P Lam

http://www.w3.org/2001/XMLSchema#string

Jacob P Kelly

http://www.w3.org/2001/XMLSchema#string

Keld Kjeldsen

http://www.w3.org/2001/XMLSchema#string

Martin R Cowie

http://www.w3.org/2001/XMLSchema#string

Mona Fiuzat

http://www.w3.org/2001/XMLSchema#string

Robert J Mentz

http://www.w3.org/2001/XMLSchema#string

Thomas G von Lueder

http://www.w3.org/2001/XMLSchema#string

P2860

What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

Adaptive servoventilation for treatment of sleep-disordered breathing in heart failure: a systematic review and meta-analysis

Trends in prevalence and outcome of heart failure with preserved ejection fraction

Outcome of heart failure with preserved ejection fraction in a population-based study

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Frailty assessment in the cardiovascular care of older adults

Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

P304

2281-2293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2014.08.036

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

Ewa A Jankowska

Carolyn S P Lam

Christopher M O'Connor

P577

2014-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268689838

http://www.w3.org/2001/XMLSchema#string

P698

25456761

http://www.w3.org/2001/XMLSchema#string

P921

P932

4254505

http://www.w3.org/2001/XMLSchema#string